^
Association details:
| Biomarker: | TRIP13 mutation + MYC mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | P5091 (USP47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression
Published date:
11/06/2019
Excerpt:
Kaplan-Meier analyses demonstrated that expression of TRIP13 TG/ Em-MYC TG decreased overall survival by greater than 25% compared to TRIP13 WT/ Em-MYC TG mice. Treatment of TRIP13 TG/ Em-MYC TG mice with a USP7 inhibitor, P5091, rescued this phenotype, restored overall survival to nearly that of TRIP13 WT/ Em-MYC TG mice. These data indicate that USP7 plays a key role in TRIP13-induced tumor progression.
DOI:
https://doi.org/10.1182/blood-2019-123818
